Corticosteroids: options in the era of steroid-sparing therapy
- PMID: 15968264
- DOI: 10.1016/j.jaad.2005.04.030
Corticosteroids: options in the era of steroid-sparing therapy
Abstract
Topical corticosteroids remain the most commonly used topical treatments for inflammatory dermatoses, including psoriasis and atopic dermatitis. Topical corticosteroids are available in a variety of vehicles-creams, ointments, lotions, gels, and, more recently, foam. The vehicle used can substantially affect the individual agent's clinical action, potency, and acceptability to the patient. Moreover, some vehicles are better suited for specific body areas. Selection of the appropriate product should be determined by area of usage, physician experience, cost, and patient preference, particularly regarding vehicle. Although topical corticosteroids are associated with several side effects, including skin atrophy, telangiectases, purpura, and striae formation, appropriate usage can minimize these occurrences. Judicious use includes short-term, appropriate application as initial monotherapy or in combination strategies with other therapeutic agents that ideally possess complementing mechanisms of action. Examples include pulsing with high-potency topical corticosteroids and combination regimens with other topical agents such as topical calcineurin inhibitors, calcipotriene, or tazarotene. Appropriate education of patients and caregivers alike will facilitate the optimal use of these medications.
Similar articles
-
Mechanisms of action of topical therapies and the rationale for combination therapy.J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S17-25. doi: 10.1016/j.jaad.2005.04.027. J Am Acad Dermatol. 2005. PMID: 15968260 Review.
-
A clinician's paradigm in the treatment of atopic dermatitis.J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S70-7. doi: 10.1016/j.jaad.2005.04.032. J Am Acad Dermatol. 2005. PMID: 15968266 Review.
-
Therapeutic options in the treatment of psoriasis and atopic dermatitis.J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S3-16. doi: 10.1016/j.jaad.2005.04.026. J Am Acad Dermatol. 2005. PMID: 15968262 Review.
-
Topical application of calcipotriene and corticosteroids: combination regimens.J Am Acad Dermatol. 1997 Sep;37(3 Pt 2):S55-8. J Am Acad Dermatol. 1997. PMID: 9344186 Review.
-
Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis.J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S39-49. doi: 10.1016/j.jaad.2005.04.029. J Am Acad Dermatol. 2005. PMID: 15968263 Review.
Cited by
-
The decoy oligodeoxynucleotide against HIF-1α and STAT5 ameliorates atopic dermatitis-like mouse model.Mol Ther Nucleic Acids. 2023 Sep 20;34:102036. doi: 10.1016/j.omtn.2023.102036. eCollection 2023 Dec 12. Mol Ther Nucleic Acids. 2023. PMID: 37799329 Free PMC article.
-
The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update.Front Mol Biosci. 2023 Aug 16;10:1159404. doi: 10.3389/fmolb.2023.1159404. eCollection 2023. Front Mol Biosci. 2023. PMID: 37654796 Free PMC article. Review.
-
Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis.Expert Rev Clin Pharmacol. 2023 Feb;16(2):119-131. doi: 10.1080/17512433.2023.2173172. Epub 2023 Feb 6. Expert Rev Clin Pharmacol. 2023. PMID: 36705936 Free PMC article. Review.
-
Melittin-Carrying Nanoparticle Suppress T Cell-Driven Immunity in a Murine Allergic Dermatitis Model.Adv Sci (Weinh). 2023 Mar;10(7):e2204184. doi: 10.1002/advs.202204184. Epub 2023 Jan 13. Adv Sci (Weinh). 2023. PMID: 36638280 Free PMC article.
-
Callicarpa dichotoma Leaf Extract Alleviates Atopic Dermatitis through the Suppression of T Cells and Keratinocytes Activation.Pharmaceuticals (Basel). 2022 Oct 18;15(10):1280. doi: 10.3390/ph15101280. Pharmaceuticals (Basel). 2022. PMID: 36297392 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
